Intuitive Surgical, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +35

What Could Lift ISRG Stock?

Company update AI-generated analysis

πŸ“‰ Intuitive Surgical (ISRG) stock has declined 8.2% over the past twelve months while the S&P 500 returned 17.1%.

πŸ’° The Instruments and Accessories segment generated $6.0 billion of the company's $10.1 billion fiscal 2025 revenue.

πŸš€ A scenario assuming 17.6% annual revenue growth over three years could result in a 78.9% stock price increase.

πŸ“Š Approximately 83% of the projected gain in the recovery scenario comes from higher revenue rather than valuation expansion.

πŸ” Total da Vinci procedures grew 16% in fiscal Q2 2026 according to management's July 16, 2026 earnings call.

πŸ₯ The newer da Vinci 5 system comprised 246 of the 468 systems placed in the second quarter of fiscal 2026.

⚠️ Management indicated that growth in US procedures has moderated, particularly for elective surgeries patients can delay.

πŸ’Έ Starting in the first half of 2027, Intuitive plans to lower per-use pricing on some instruments without specifying the financial impact.

πŸ“‰ A flat P/E multiple would trim returns more than a slower revenue growth rate in downside scenarios.

πŸ›‘οΈ Revenue has grown in each of the last three fiscal years, with 21% growth recorded in the most recent year.

Bullish Signals
  • Total da Vinci procedures grew 16% in fiscal Q2 2026, demonstrating strong operational momentum.
  • The newer da Vinci 5 system accounted for 246 of the 468 systems placed in the quarter, indicating successful adoption.
  • Intuitive Surgical has achieved revenue growth in each of its last three fiscal years, including a 21% increase in the most recent year.
  • The company's largest revenue segment, Instruments and Accessories, contributed $6.0 billion to fiscal 2025 revenue.
Risk Factors
  • Management stated that growth in US procedures has moderated, primarily affecting elective surgeries patients can postpone.
  • The company plans to lower per-use pricing on some instruments starting in the first half of 2027, which may impact margins.
  • Valuation multiple compression poses significant downside risk, as a flat P/E would trim returns more than slower revenue growth.
  • The stock has lost 8.2% over the past twelve months while the broader market gained 17.1%, indicating recent underperformance.
Full Analysis
Intuitive Surgical (ISRG) has underperformed the broader market over the past year, losing 8.2% compared to the S&P 500's 17.1% gain. The article analyzes the specific business drivers required for ISRG stock to recover and grow significantly over a three-year horizon. It posits that substantial revenue growth from its core Instruments and Accessories segment is the primary engine needed, supported by a potential recovery in valuation multiples. The analysis highlights that Intuitive's largest revenue source, the Instruments and Accessories segment, generated $6.0 billion of its $10.1 billion fiscal 2025 revenue. The scenario assumes annual revenue growth of 17.6% over three years, which would drive approximately 83% of the projected stock gain. This growth is contingent on hospitals continuing to adopt newer da Vinci systems and increasing the volume of procedures performed. However, the outlook faces headwinds including management's guidance for moderated US procedure growth and a planned price reduction on certain instruments starting in the first half of 2027. The article notes that while revenue remains the main source of potential upside, valuation multiple compression poses significant downside risk to total returns if market sentiment does not improve. Intuitive Surgical reported a 16% increase in total procedures during fiscal Q2 2026, with the newer da Vinci 5 system accounting for the majority of new placements. Despite this operational strength, the company's ability to sustain high growth depends on overcoming the slowdown in elective procedures and maintaining margins despite pricing adjustments.